Three independent studies have reported that high tumour pAkt immunoreactivitiy is associated with a poor clinical outcome (biochemical relapse assessed with serum prostate-specific antigen (PSA) [9], [12], and survival [13]). The gene discussed is KLK3; the disease is neoplasm.